Results from EXCELS suggest that omalizumab therapy is not associated with an increased risk of malignancy.
No takes yet. Share an insight, caveat, or question.
Long et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: